Weight Loss and Obesity Management Market Report 2026

The weight loss and obesity management market size has grown strongly in recent years. It will grow from $257.34 billion in 2025 to $278.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising prevalence of obesity-related health conditions, increasing public health awareness initiatives, expansion of fitness and wellness centers, growing acceptance of medical weight management, availability of diverse weight loss solutions.

The weight loss and obesity management market size is expected to see strong growth in the next few years. It will grow to $379.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing adoption of digital therapeutics, rising demand for personalized obesity treatments, expansion of employer-sponsored wellness programs, growing integration of ai-based health analytics, increased focus on long-term weight maintenance. Major trends in the forecast period include increasing adoption of personalized weight management programs, rising integration of digital health platforms, growing use of data-driven behavioral therapy, expansion of medically supervised weight loss solutions, enhanced focus on preventive health outcomes.

The growing awareness of nutrition and healthy lifestyles is expected to drive the growth of the weight loss and obesity management market in the coming years. Nutrition and healthy lifestyles involve maintaining a balanced diet and engaging in physical activities that support long-term health. Awareness of these practices is increasing as the internet and social media provide easy access to information, tips, and advice, enabling people to learn more about healthy eating and habits. This heightened awareness supports weight loss and obesity management by helping individuals make informed dietary choices, adopt regular physical activity, and maintain sustainable, healthy behaviors. For example, in June 2024, according to the International Food Information Council (IFIC), a US-based non-profit organization, 54% of Americans reported following a specific diet or eating pattern over the past year. Many individuals aim to increase their protein intake, which rose from 59% in 2022 to 67% in 2023, reaching 71% in 2024. Additionally, about half of consumers are seeking to consume more fresh foods, widely regarded as the healthiest options. Therefore, rising awareness of healthy eating and dietary habits is driving growth in the weight loss and obesity management market.

Key companies in the weight loss and obesity management market are focusing on developing advanced solutions, such as dual incretin GLP-1/GIP receptor agonists, to improve treatment efficacy, support sustained weight reduction, and enhance metabolic outcomes. Dual incretin agonists are medications that simultaneously activate GLP-1 and GIP receptors, reducing appetite, slowing gastric emptying, and improving insulin sensitivity, offering more potent and long-lasting effects than traditional single-target therapies. For instance, in November 2023, Eli Lilly, a US-based pharmaceutical company, launched Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Tirzepatide mimics the activity of two hormones to prolong satiety, suppress hunger, and support clinically significant, sustained weight loss, with convenient once-weekly administration. This therapy represents a significant advancement in obesity care by providing an effective, long-term management option for patients.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm specializing in diabetes, oncology, immunology, and obesity-related treatments, acquired Versanis Bio for an undisclosed amount. Through this acquisition, Lilly aims to improve patient outcomes in cardiometabolic diseases by strengthening its obesity treatment pipeline with innovative therapeutic options. Versanis Bio Inc., based in the US, specializes in developing treatments for weight loss and obesity management.

Major companies operating in the weight loss and obesity management market are F. Hoffmann-La Roche Ltd., Medtronic plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Apollo Endosurgery Inc., Biocon Limited, WW International Inc., Equinox Holdings Inc., Noom Inc., Jenny Craig Inc., Nutrisystem Inc., Virta Health Corp., Allurion Technologies Inc., Atkins Nutritionals Inc., ReShape Lifesciences Inc., Nalpropion Pharmaceuticals Inc., OptiBiotix Health plc, PRISTYN CARE.

North America was the largest region in the weight loss and obesity management market in 2025. The regions covered in the weight loss and obesity management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the weight loss and obesity management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the weight loss and obesity management market by increasing costs of imported medical devices, fitness equipment, pharmaceutical ingredients, and digital health infrastructure components. Healthcare providers and wellness centers in North America and Europe are most affected due to reliance on imported equipment and formulations, while Asia-Pacific faces cost pressures in service delivery expansion. These tariffs are increasing service pricing and limiting access in cost-sensitive markets. However, they are also encouraging domestic manufacturing of equipment, local formulation of supplements and drugs, and regional expansion of digital health platforms to reduce import dependency.

The weight loss and obesity management market research report is one of a series of new reports that provides weight loss and obesity management market statistics, including weight loss and obesity management industry global market size, regional shares, competitors with a weight loss and obesity management market share, detailed weight loss and obesity management market segments, market trends and opportunities, and any further data you may need to thrive in the weight loss and obesity management industry. This weight loss and obesity management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Weight loss and obesity management refers to the structured process of reducing and controlling body weight, particularly in individuals classified as overweight or obese, through a combination of dietary modifications, physical activity, behavioral therapy, medications, and sometimes surgical interventions. The goal is to improve overall health outcomes, lower the risk of obesity-related conditions such as type 2 diabetes, cardiovascular diseases, and hypertension, and enhance quality of life.

The primary products and services in weight loss and obesity management include drugs, supplements, equipment, and services. Weight control drugs are medications designed to reduce appetite, block fat absorption, or increase metabolism to support medically supervised weight loss. These drugs are available as prescription and over-the-counter (OTC) options. The target age groups include children, adults, and the geriatric population. They are distributed through various channels, including institutional and retail sales, and are utilized by multiple industries, such as fitness centers, slimming centers, consulting services, and online weight loss programs.

The weight loss and obesity management market consists of revenues earned by entities by providing services such as dietary and nutritional counseling, fitness and exercise programs, behavioral therapy and lifestyle coaching, medical weight loss programs, surgical weight loss procedures, meal replacement and supplement programs, online and app-based coaching services. The market value includes the value of related goods sold by the service provider or included within the service offering. The weight loss and obesity management market also includes sales of dietary supplements, meal replacements, fitness equipment, surgical devices, prescription medications, mobile health apps, and low-calorie food and beverages. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.